<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308086</url>
  </required_header>
  <id_info>
    <org_study_id>CT/09.12</org_study_id>
    <nct_id>NCT01308086</nct_id>
  </id_info>
  <brief_title>Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer</brief_title>
  <official_title>A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare whether a 3-month treatment is at least not inferior
      to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs. 8 cycles) in terms of
      RFS in patients with high risk stage II or stage III radically resected colon cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six months of adjuvant chemotherapy with 5-FU and oxaliplatin for patients with stage III
      colon cancer is the world-wide standard of care, based on the MOSAIC and C-07 trials.
      However, it leads to significant cost, toxicity, and inconvenience. In particular, the onset
      of oxaliplatin induced cumulative dose-dependent neuropathies is a significant issue. The
      ability to maintain efficacy with a reduced duration of therapy would have clear advantage to
      patients, to providers, and to the health care system.

      Multiple large trials in the 1990s demonstrated that the previous standard of 12 months of
      therapy could be reduced to 6 months. A single small trial with 5-FU alone demonstrated
      similar outcomes for 3 versus 6 months of therapy. Thus, it is proposed to definitively
      evaluate the non-inferiority of 3 months of oxaliplatin-based adjuvant chemotherapy versus
      the current standard of 6 months. The primary endpoint will be disease-free survival (DFS).

      It is essential to have sufficient power to eliminate the possibility of clinically
      meaningful inferiority of 3 months of therapy: a huge number of patients will be necessary.
      Previous efforts and experience have conclusively demonstrated that in colon cancer, a
      single, global trial is impractical. Consequently, an international, prospective pooled
      analysis will be performed, gathering data of independent trials run in different countries,
      to answer the single primary hypothesis that 3 months of adjuvant therapy with FOLFOX/XELOX
      is non-inferior to the current standard of 6 months. Among six planned countries, the Greek
      intergroup will conduct one of these trials.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>3-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profil according to NCI-CTAE v 3.0</measure>
    <time_frame>q2w</time_frame>
    <description>Percentage (%) of treatments delays and interaptions in each arm Percentage (%) of dose received versus planned dose in each arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2000</enrollment>
  <condition>CRC</condition>
  <arm_group>
    <arm_group_label>FOLFOX 4 - 6months or XELOX -6months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX4 -3months or XELOX -3months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 &amp; 2, q2w, for 12 cycles</description>
    <arm_group_label>FOLFOX 4 - 6months or XELOX -6months</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin 200mg/m2 IV in 2 hours, days 1 &amp; 2, q2w, for 12 cycles</description>
    <arm_group_label>FOLFOX 4 - 6months or XELOX -6months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles</description>
    <arm_group_label>FOLFOX 4 - 6months or XELOX -6months</arm_group_label>
    <other_name>LoHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles</description>
    <arm_group_label>FOLFOX 4 - 6months or XELOX -6months</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles</description>
    <arm_group_label>FOLFOX 4 - 6months or XELOX -6months</arm_group_label>
    <other_name>LoHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 &amp; 2, q2w, for 6 cycles</description>
    <arm_group_label>FOLFOX4 -3months or XELOX -3months</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin 200mg/m2 IV in 2 hours, days 1 &amp; 2, q2w, for 6 cycles</description>
    <arm_group_label>FOLFOX4 -3months or XELOX -3months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles</description>
    <arm_group_label>FOLFOX4 -3months or XELOX -3months</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles</description>
    <arm_group_label>FOLFOX4 -3months or XELOX -3months</arm_group_label>
    <other_name>LoHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles</description>
    <arm_group_label>FOLFOX4 -3months or XELOX -3months</arm_group_label>
    <other_name>LoHP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- - confirmed adenocarcinoma of the colon or rectum stage III or stage
             with at least one of the follow characteristics T4 tumours, undifferentiated tumor
             grade &gt;3, bowel obstruction or perforation, vascular or lymphatic or perineural
             invasion, &lt;12 nodes examined, Stage IV.

          -  Signed written informed consent

          -  Randomization between 2 -8 weeks after curative surgery

          -  Age &gt;18 years

          -  ECOG performance Status 0-1

          -  Pretreatment CEA within UNL

          -  Post-menopausal women or women willing to accept the use of an effective
             contraception. Pre-menopausal women should have a negative pregnancy test within 72
             hours prior to randomization

          -  Men should also accept to use an effective contraception

          -  R0 resections

        Exclusion Criteria:

          -  Evidence of metastatic disease (including presence of tumor cells in ascites or
             peritoneal carcinomatosis resected &quot;en bloc&quot;)

          -  Evidence of other malignancies within the last 5 years (other than curatively treated
             basal cell carcinoma of the skin and/or in situ carcinoma of the cervix)

          -  No pregnant or lactating women

          -  Presence of clinically relevant cardiovascular disease

          -  Presenc of medical history or current evidence of CNS disease

          -  Presence of peripheral neuropathy ≤ grade 1 (CTCAE v. 3.0)

          -  History of clinically relevant psychiatric disability, precluding informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Souglakos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>capecitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>5 fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

